Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis
Conditions
Interventions
VX-121
TEZ
+4 more
Locations
26
United States
Keck Medical Center of University of Southern California
Los Angeles, California, United States
Kaiser Permanente
Oakland, California, United States
University of Kentucky.
Lexington, Kentucky, United States
Tulane Medical Center
New Orleans, Louisiana, United States
Boston Children's Hospital
Boston, Massachusetts, United States
University of Minnesota
Minneapolis, Minnesota, United States
Start Date
April 30, 2019
Primary Completion Date
December 10, 2019
Completion Date
December 10, 2019
Last Updated
April 20, 2023
NCT04469439
NCT06154447
NCT06984679
NCT02417740
NCT05359991
NCT07484607
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions